Investigators to Report use of the Cancion(R) System in Patients
Hospitalized with Heart Failure
LAKE FOREST, Calif., Feb. 13 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to treat heart failure, announced today that the company's MOMENTUM Trial Abstract was accepted for Late Breaking Clinical Trial presentation at the upcoming annual American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial evaluated the percutaneous Cancion System in patients with acute decompensated heart failure.
Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and National Principal Investigator for the MOMENTUM Trial, will present, "Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results of the MOMENTUM Trial," Tuesday, April 1, 2008, from 1:45 pm to 2:00 pm, at the McCormick Place convention center, North Hall B1.
"MOMENTUM is a landmark study examining the hemodynamic and clinical effects of the Cancion System in managing patients hospitalized with heart failure inadequately responsive to medical therapy," stated Dr. Barry Greenberg. Mr. Ken Charhut, President and CEO added, "We are delighted that the MOMENTUM Trial Abstract has been accepted for presentation at the ACC conference and look forward to Dr Greenberg's presentation and dialogue."
About Heart Failure
Over 5 million Americans suffer from heart failure, a condition in
which the heart becomes weakened and cannot pump blood efficiently. Heart
failure is caused by coronary artery disease, past myocardial infarctions,
cardiomyopathy and other underlying cardiovascular disorders, and it is
characterized by shortness of breath, functional impairment, and edema. In
the U.S., heart failure results in over 1 million hospitalizations annually
|SOURCE Orqis Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved